12:00 AM
 | 
Sep 14, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ataluren: Phase III started

PTC began a double-blind, placebo-controlled, international Phase III trial to evaluate oral ataluren given morning, midday, and evening at 10, 10 and 20 mg/kg doses, respectively, for 48 weeks in about 208 patients....

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >